Stoked Bio

AI-assisted MOSAIC platform for small-molecule drugs against resistant infections, cancers, Crohn's

Website: https://stokedbio.com

Cover Block
Name Stoked Bio
Tagline AI-assisted MOSAIC platform for small-molecule drugs against resistant infections, cancers, Crohn's
Headquarters Canada
Stage Seed
Business Model B2B
Industry Healthtech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Label Seed (total disclosed ~$2,500,000)

Links

Executive Summary

Stoked Bio is a preclinical biotechnology startup using a proprietary, biology-first AI platform to discover novel small-molecule drugs for conditions with high unmet need, including antimicrobial resistance, glioblastoma, and Crohn's disease. The company's immediate investor appeal lies in its exclusive control over a promising clinical asset, Enterololin, and its academic roots in a lab with a published track record of antibiotic discovery [GlobeNewswire, Feb 2026] [MIT News, 2025].

The venture originated from the Stokes Lab at McMaster University, translating academic research into a commercial drug discovery engine called MOSAIC. This platform is designed to identify and optimize patentable drug candidates, advancing them to a stage ready for partnership with larger pharmaceutical companies. The founding team combines deep scientific expertise from McMaster with commercial leadership.

Capitalization is light, with a seed round of undisclosed size recently closed, supported by participation in the Creative Destruction Lab accelerator [BioSpace, Unknown] [Creative Destruction Lab, Unknown]. The business model is asset-centric, aiming to license or out-license programs rather than build commercial infrastructure. Over the coming 12-18 months, the critical milestones to watch are preclinical data readouts for Enterololin, the progression of other pipeline candidates, and the securing of a first pharmaceutical development partnership.

Data Accuracy: YELLOW -- Core company claims are self-published; key facts like funding size and team backgrounds lack independent corroboration.

Taxonomy Snapshot

Axis Classification
Stage Seed
Business Model B2B
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Seed (total disclosed ~$2,500,000)

How the Company Got Here

Stoked Bio is a Canadian biotechnology company that emerged from academic research at McMaster University, specifically the Stokes Lab. Its public identity is anchored by a recent milestone: securing an exclusive global license for a novel antibiotic program from its academic birthplace.

The founding team includes Jonathan Stokes, whose lab originated the core technology, alongside Jeff Skinner, who serves as CEO, and Chris Sinclair. The company has participated in the Creative Destruction Lab accelerator program [Creative Destruction Lab].

A key chronological milestone occurred on February 18, 2026, when Stoked Bio announced it had secured an exclusive global license from McMaster University for Enterololin, a narrow-spectrum antibiotic initially researched for Crohn's disease [GlobeNewswire, Feb 2026]. The company also announced the closing of a seed financing round [BioSpace].

Data Accuracy: YELLOW -- Company website and press releases provide core details; founding year and specific HQ location are not publicly available.

Product and Technology

Stoked Bio's core asset is the MOSAIC platform, a biology-driven AI system designed to discover and optimize small-molecule drug candidates from initial screening to Investigational New Drug (IND) readiness [stokedbio.com/what-we-do/]. The platform's stated purpose is to generate patentable assets for partnering with pharmaceutical companies, focusing on areas of high unmet need like antimicrobial resistance and cancers resistant to current treatments [Creative Destruction Lab].

The technology is a full-stack approach, integrating AI for molecular property prediction and design across any therapeutic area [stokedbio.com/what-we-do/]. Its first tangible output is the Enterololin program, a narrow-spectrum antibiotic for Crohn's disease for which Stoked Bio secured an exclusive global license from McMaster University in February 2026 [GlobeNewswire, Feb 2026]. The company claims to have four initial novel programs targeting resistant infections and cancer [Perplexity Sonar Pro]. The platform's development originated from the Stokes Lab at McMaster University.

Data Accuracy: YELLOW -- Core platform claims are from the company website; the license agreement is confirmed by a press release. Specific technical capabilities and program details lack independent verification.

Where the Demand Sits

The urgency to develop new small-molecule therapeutics is driven by a convergence of rising antimicrobial resistance, intractable cancers, and the high failure rates of traditional drug discovery pipelines.

Metric Value
Antimicrobial Resistance (AMR) Drug Market 12.1 $B (2030)
Glioblastoma Therapeutics Market 3.2 $B (2024)
Inflammatory Bowel Disease (IBD) Drug Market 25 $B

Key demand drivers extend beyond market size. The primary tailwind is the escalating global health threat of antimicrobial resistance, which the WHO classifies as one of the top ten global public health threats [WHO]. This has spurred governmental and non-profit funding initiatives, such as the CARB-X accelerator and the AMR Action Fund. A second driver is the persistent high failure rate in oncology drug development, creating demand for novel discovery methods. The company's exclusive license for Enterololin also positions it within a shift towards microbiome-targeted therapies, a growing sub-sector within gastroenterology [Nature Reviews Gastroenterology & Hepatology].

Regulatory pathways for drugs targeting unmet medical needs, like Qualified Infectious Disease Product (QIDP) designation in the U.S., can offer incentives such as priority review and extended market exclusivity. The biotech funding environment remains constrained, making capital efficiency and clear de-risking milestones critical.

Data Accuracy: YELLOW -- Market sizing figures are drawn from analogous third-party industry reports, not company-provided projections. Therapeutic area focus is confirmed by company sources.

Competitive Landscape

Stoked Bio enters a competitive field by focusing on a biology-first AI platform to generate small-molecule drug candidates for specific, high-burden conditions.

Company Positioning Stage / Funding Notable Differentiator Source
Stoked Bio AI-assisted (MOSAIC) platform for small-molecule discovery against resistant infections, cancers, Crohn's. Seed stage; undisclosed round. Exclusive global license for Enterololin antibiotic from McMaster University; academic spinout with biology-driven AI approach. [GlobeNewswire, Feb 2026]; [Creative Destruction Lab]
Absci Generative AI for de novo antibody and protein drug discovery. Public (NASDAQ: ABSI); $200M+ in funding. Integrated wet-lab platform for zero-shot generation and validation of novel biologics. [Absci corporate filings, 2025]
Recursion AI-powered drug discovery platform mapping cellular biology for multiple therapeutic areas. Public (NASDAQ: RXRX); $1B+ in funding. Massive proprietary dataset of phenomics images and automated wet-lab validation at scale. [Recursion investor presentations, 2025]
Exscientia AI-driven small-molecule design and clinical development. Public (NASDAQ: EXAI); $500M+ in funding. Multiple AI-designed molecules in clinical trials; established partnerships with major pharma. [Exscientia corporate website, 2025]

Stoked Bio's defensible edge today rests on its exclusive access to foundational intellectual property and the academic pedigree of its platform. The exclusive global license for Enterololin provides a tangible, patent-protected asset that de-risks at least one program's initial development path [GlobeNewswire, Feb 2026]. Furthermore, the MOSAIC platform originated within the Stokes Lab at McMaster University, suggesting a deep integration of biological expertise with computational tools [Synapse Consortium].

Data Accuracy: YELLOW -- Competitor profiles are based on public corporate materials; Stoked Bio's differentiation is cited from press releases and program descriptions.

Opportunity

If Stoked Bio's platform can systematically generate novel, patentable drug candidates against intractable diseases, the commercial prize is a portfolio of high-value clinical assets, each representing a potential billion-dollar licensing deal or acquisition by a major pharmaceutical company.

The headline opportunity is to become a recognized, asset-generating biotech platform. The most plausible large outcome is that Stoked Bio's MOSAIC platform proves its repeatability by advancing multiple programs from discovery to IND-ready packages. The evidence for this reachable outcome begins with the company's academic roots and exclusive license. Originating from the Stokes Lab at McMaster University provides a foundation in published biology and a direct channel to university intellectual property, as demonstrated by the February 2026 exclusive global license for Enterololin [GlobeNewswire, Feb 2026].

Scenario What happens Catalyst Why it's plausible
Platform Partnership A major pharma enters a multi-program discovery alliance, providing non-dilutive funding and downstream rights. The company publishes robust preclinical data for a second, wholly-owned program generated by MOSAIC. The company's stated focus is advancing candidates to IND readiness for partnering [stokedbio.com]. The Creative Destruction Lab affiliation provides a network to potential corporate partners [Creative Destruction Lab].
Portfolio Build & Exit The company advances 2-3 assets through Phase I proof-of-concept, becoming an attractive acquisition target for a mid-cap biotech. Successful completion of a Series A round to fund initial clinical trials. The initial wedge targets high-need areas (antimicrobial resistance, glioblastoma) where clinical success commands significant premiums, and the academic spinout structure is a common precursor to trade sales.

Data Accuracy: YELLOW -- The core platform claim and license are publicly cited, but growth scenarios are extrapolated from the company's stated model without public validation of partnership talks or pipeline progress beyond the first license.

Sources

Articles about Stoked Bio

Related companies

Topics

View on Startuply.vc